ClinicalTrials.gg
Sign In

Lymphoma, Mantle-Cell clinical trials

The registry lists 1,220 studies for Lymphoma, Mantle-Cell across more than 10 countries. 154 are recruiting or about to start. 341 of them are mainly about Lymphoma, Mantle-Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

ClinicalTrials.gov finds 1,255 studies for Lymphoma, Mantle-Cell. How that becomes 1,220 here

This page counts the studies the registry files under Lymphoma, Mantle-Cell, and those it files under no condition that list Lymphoma, Mantle-Cellthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,255Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −9List Lymphoma, Mantle-Cell as a condition, but the registry did not file them under itMost often written as “Mantle Cell Lymphoma Recurrent” (4), “Mantle Cell Lymphoma Refractory” (2), and “B-cell Mantle Cell Lymphoma” (1). The registry filed them under other conditions only, most often Leukemia, Lymphocytic, Chronic, B-Cell (6) and Lymphoma, Large B-Cell, Diffuse (5).
  3. −26Match it another way12 name it in the title, 1 in a keyword, and 13 by a synonym or other text the search reads.
  4. 1,220The count on this page9 of them list Lymphoma, Mantle-Cell in their own words; the registry filed them under no condition.

Get an email when these change. Save the Lymphoma, Mantle-Cell studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
683
Terminated
167
Recruiting
125
Active, not recruiting
85
Status unknown
76
Withdrawn
51

Phase

Phase 2
609
Phase 1
521
Phase 3
87
Early Phase 1
15
Phase 4
6

Where

United States
905
China
98
France
82
Italy
81
Germany
74
United Kingdom
63

Who runs them

National Cancer Institute (NCI) (101) · Fred Hutchinson Cancer Center (70) · M.D. Anderson Cancer Center (47) · City of Hope Medical Center (41) · Memorial Sloan Kettering Cancer Center (32) · Masonic Cancer Center, University of Minnesota (26) · Case Comprehensive Cancer Center (24) · Mayo Clinic (22)

What is being tested here

Drugs under test in Lymphoma, Mantle-Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Zanubrutinib12217
Rituximab1114153
Glofitamab10012
Obinutuzumab8016
Pirtobrutinib8112
Orelabrutinib829
Lenalidomide5444
Acalabrutinib5226
Venetoclax5122
Sonrotoclax516

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 44 open · Alkylating agents 5 open · Antimetabolites 4 open · Antibody-drug conjugates (ADCs) 4 open · Proteasome inhibitors 1 open

Coming up

14phase 3 studies under way
72studies finish main data collection within a year5 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger. 14 (11%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (2%) take healthy volunteers.

Recruiting studies that take each age, of 125
AgeWomenMen
107 (6%)7 (6%)
18119 (95%)119 (95%)
30121 (97%)121 (97%)
40121 (97%)121 (97%)
50121 (97%)121 (97%)
65124 (99%)124 (99%)
75119 (95%)119 (95%)
85101 (81%)101 (81%)

Across all 1,220 studies, recruiting or not: 22% stop at 75 or younger and 10% at 65; 18% take children; 0% are for women only and <1% for men only; 1% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Lymphoma, Mantle-Cell studies take

Of 183 phase 2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 63 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 161 mo36–82 · 128 studies57 mo31–71 · 55 studies64 mo39–98 · 73 studies
Phase 1/275 mo45–114 · 77 studies—78 mo49–122 · 51 studies
Phase 263 mo38–106 · 183 studies49 mo22–87 · 30 studies64 mo40–108 · 153 studies
Phase 397 mo68–… · 27 studies——
Interventional, no phase47 mo22–144 · 18 studies——
Observational60 mo44–121 · 38 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 14, 2026.

Started recruiting2

Results posted1

Newly registered3

Studies

Recruiting first, then most recently updated. Showing 50 of 1,220. Browse all 1,220 → or search them.